Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 5:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ovarian Insufficiency Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Hormone Replacement in Young Women With Premature Ovarian Failure

NCT00001951
View directory record Official record
Conditions
Healthy, Osteoporosis, Premature Ovarian Failure
Interventions
TMTDS
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 32 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2007 · Synced Sep 9, 2026, 5:52 PM EDT
Withdrawn Early Phase 1 Interventional

The Use of DHEA in Women With Premature Ovarian Failure

NCT01129947
View directory record Official record
Conditions
Premature Ovarian Failure
Interventions
DHEA
Drug
Lead sponsor
Virginia Center for Reproductive Medicine
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Reston, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Sep 9, 2026, 5:52 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy

NCT01986764
View directory record Official record
Conditions
Planned RRSO
Interventions
Lisdexamfetamine, Estradiol, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 48 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 9, 2026, 5:52 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

NCT04561362
View directory record Official record
Conditions
Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
Interventions
BT8009, Pembrolizumab
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Ocala, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 9, 2026, 5:52 PM EDT
Suspended Phase 1 Interventional

A Proof of Concept Study to Evaluate Exosomes From Human Mesenchymal Stem Cells in Women With Premature Ovarian Insufficiency (POI)

NCT06072794
View directory record Official record
Conditions
Premature Ovarian Insufficiency, Diminished Ovarian Reserve
Interventions
VL-PX10
Drug
Lead sponsor
Vitti Labs, LLC
Industry
Eligibility
18 Years to 43 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 9, 2026, 5:52 PM EDT
Terminated No phase listed Observational

The Natural History of Reproductive and Overall Health in Girls and Women With a Pre-Mutation in the FMR1 Gene; Creation of a Patient Registry

NCT01187524
View directory record Official record
Conditions
Fragile X Syndrome, FMR1 Premutation, Primary Ovairan Insufficiency, Premature Ovarian Failure, Premature Menopause
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 9, 2026, 5:52 PM EDT
Recruiting No phase listed Observational

Identifying Genome Variants in Non-Obstructive Azoospermia (NOA) or Primary Ovarian Insufficiency (POI)

NCT07357701
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Azoospermia, Oligospermia
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Bethesda, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 9, 2026, 5:52 PM EDT
Not listed Phase 1 Interventional

Ovarian Rejuvenation Using Platelet Rich Plasma (PRP) & Autologous Tissue Stromal Vascular Fraction (tSVF) and Cell Enriched tSVF

NCT04444245
View directory record Official record
Conditions
Ovarian Failure, Perimenopausal Disorder, Hormone Disturbance
Interventions
lipoaspiration harvest tSVF, Platelet Rich Plasma, Endovaginal Ultrasound, Cellular Isolation cSVF, Normal Saline (NS) .9% 10 mL Injection, emulsification tSVF
Procedure · Device · Drug
Lead sponsor
Black Tie Medical, Inc.
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 9, 2026, 5:52 PM EDT
Recruiting No phase listed Observational

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

NCT05567198
View directory record Official record
Conditions
Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 3 Interventional

Estrogen Treatment (Oral vs. Patches) in Turner Syndrome

NCT00140998
View directory record Official record
Conditions
Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions
17 beta estradiol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years to 16 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Sep 9, 2026, 5:52 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency

NCT06866119
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Premature Menopause, Metabolic Complications, Endothelial Function (FMD), Estrogen Replacement Therapy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 40 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 9, 2026, 5:52 PM EDT
Recruiting Not applicable Interventional

Cryopreservation of Ovarian Tissue

NCT01558544
View directory record Official record
Conditions
Cancer, Risk of Premature Ovarian Failure, Fertility Preservation
Interventions
surgery to remove ovaries or high dose chemotherapy
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
Up to 45 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 9, 2026, 5:52 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Ovarian Tissue Allo-transplantation

NCT06673004
View directory record Official record
Conditions
Ovarian Failure, Ovarian Insufficiency, Menopause Ovarian Failure, Menopause, Premature, Infertility, Female, Endocrine Female Infertility
Interventions
Ovarian tissue allo-transplantation
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility Study for Development of an Early Test for Ovarian Failure

NCT00006156
View directory record Official record
Conditions
Healthy, Premature Ovarian Failure
Interventions
Control, Drug: FSH
Other · Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 70 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Sep 9, 2026, 5:52 PM EDT
Completed No phase listed Observational

Ovarian Stem Cells From Women With Ovarian Insufficiency

NCT01702935
View directory record Official record
Conditions
Infertility
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Not applicable Interventional

Rejuvenation of Premature Ovarian Failure With Stem Cells

NCT02696889
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Low Ovarian Reserve, Premature Ovarian Failure
Interventions
ROSE-1 Protocol
Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Sep 9, 2026, 5:52 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Quest to Analyze One Thousand Humans Meditating

NCT06583395
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions
Advanced multi-component meditation practice
Behavioral
Lead sponsor
Tobias Moeller-Bertram
Industry
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palm Desert, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Primary Ovarian Insufficiency: Phenotype and Optimal Treatment

NCT03568708
View directory record Official record
Conditions
Primary Ovarian Insufficiency
Interventions
Transdermal Estrogen
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 18 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 9, 2026, 5:52 PM EDT
Active, not recruiting Phase 1 Interventional

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

NCT01366144
View directory record Official record
Conditions
Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma, Liver Failure, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Testicular Neoplasm, Melanoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Renal Failure, Unresectable Malignant Neoplasm, Urothelial Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
17
States / cities
Duarte, California • Sacramento, California • South Pasadena, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 9, 2026, 5:52 PM EDT
Recruiting Phase 4 Interventional

Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome

NCT06834594
View directory record Official record
Conditions
Turner Syndrome, Primary Ovarian Insufficiency (Poi)
Interventions
Micronized progesterone 200 MG, Micronized Progesterone 100 MG
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 20 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 9, 2026, 5:52 PM EDT
Withdrawn Phase 4 Interventional

Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy

NCT00507780
View directory record Official record
Conditions
Ovarian Function, Preservation of Ovarian Function
Interventions
GnRH antagonist
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
10 Years to 21 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 5:52 PM EDT
Not listed Phase 1Phase 2 Interventional

Effect of Testosterone Treatment on Embryo Quality

NCT01662466
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Female Infertility Due to Diminished Ovarian Reserve
Interventions
Testosterone cream (0.5mg per gram), DHEA, Placebo
Drug · Dietary Supplement
Lead sponsor
Center for Human Reproduction
Other
Eligibility
38 Years to 44 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
2
States / cities
New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 9, 2026, 5:52 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency

NCT06851754
View directory record Official record
Conditions
Premature Ovarian Insufficiency
Interventions
Progesterone, Estrogen Patch
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
11 Years to 19 Years · Female only
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 9, 2026, 5:52 PM EDT
Terminated Phase 3 Interventional Results available

Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer

NCT00429403
View directory record Official record
Conditions
Breast Cancer
Interventions
Goserelin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 46 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2016 · Synced Sep 9, 2026, 5:52 PM EDT